A novel FRET-based assay enables the measurement of binding affinities and kinetics for obligate binding proteins that aggregate in the absence of a partner.
Answers are grounded in this paper and cite their sources.
Novel FRET assay enables affinity measurements for aggregating proteins; extends research tools but leaves open clinical translation.
We have developed Förster resonance energy transfer (FRET)‐based experiments for measuring the binding affinity, off‐rates, and inferred on‐rates for interactions between a family of transcriptional regulators and their intrinsically disordered binding partners. It was difficult to evaluate these interactions previously, as the transcriptional regulators are obligate binding proteins that aggregate in the absence of a binding partner. The assays rely on fusion constructs where binding domains are linked by a flexible tether containing a specific protease site, with fluorescent proteins at either end that display FRET when the complex is formed. Loss of FRET is monitored after cutting the tether followed by dilution or competition with a non‐fluorescent peptide. These methods allowed a wide range of binding affinities (10−9–10−5 m) to be determined. Our data indicate that interactions of closely related proteins can have surprisingly different binding properties.
No takes yet. Share an insight, caveat, or question.
Robertson et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: